Abstract: Provided is a cosmetic use, as deodorant active agent, of an essential oil of Satureja montana comprising more than 60% by weight of geraniol and more than 5% by weight of trans-?-caryophyllene, and in particular an essential oil of Satureja montana L. ssp. variegata or Satureja Montana var. citrodoria oil. Also provided is a cosmetic method for treating human body odors, in particular the armpits or feet, which comprises applying, to human keratin materials, at least one Satureja montana essential oil comprising more than 60% by weight of geraniol and more than 5% by weight of trans-?-caryophyllene, and in particular an essential oil of Satureja montana L. ssp. variegata or Satureja Montana var. citrodoria oil or a composition containing same in a cosmetically acceptable medium.

Abstract: A pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, wherein the dosage form contains a pharmacologically active ingredient (A); an inorganic salt (B); and a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (C) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (A) is present in a controlled-release matrix comprising the inorganic salt (B) and the polyalkylene oxide (C) and wherein, under in vitro conditions, the release profile of the pharmacologically active ingredient (A) from the matrix comprises at least a time interval during which the release follows zero order kinetics.

Abstract: A skin care composition is provided that has an oil phase mixture and a water phase. The oil phase mixture has from about 5% to about 30% by weight of the composition, of a wax material and optionally from about 1% to about 20% by weight of the composition, of an oil that is liquid at room temperature. The oil phase mixture has a melting point of about 25° C. to about 50° C. The water phase has from about 0.1% to about 5%, by weight of the composition, of a superabsorbent polymer and from about 20% to about 85% by weight of the composition of water. The composition also has from about 6% to about 30%, by weight of the composition, of particulate material selected from the group consisting of starch particles, silicone elastomer particles and combinations thereof.

Abstract: A suspension of a boron containing compound in the form of crystals, powder or granulate in a solvent which contain a carbomer as dispersant. This suspension is very stable, even at high concentrations, and exhibits favourable non-Newtonian viscosity behavior, which makes it suitable in a number of applications, such as for the control of fission reactions with the generation of electric power from nuclear energy.

Abstract: A dispensable hydroalcoholic gel composition is provided. The dispensable hydroalcoholic gel includes a C1-4 alcohol, a polyacrylate thickener, and a glyceryl ester.

Abstract: A dispensable gel composition is provided. The dispensable gel composition includes a C1-4 alcohol, a polyacrylate thickener, and a diol plug-preventing additive. The dispensable gel exhibits less misdirection during dispensing from a dispensing device than gel compositions that are otherwise identical, but for the presence of the plug-preventing additive.

Abstract: A dispensable gel composition is provided. The dispensable gel composition includes a C1-4 alcohol, a polyacrylate thickener, and a plug-preventing additive. The dispensable gel exhibits less misdirection during dispensing from a dispensing device than gel compositions that are otherwise identical, but for the presence of the plug-preventing additive.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: Described herein is a method that comprises: —placing a bone material, containing hydroxyapatite and organic substances, in contact with an extraction liquid that gives rise to a first liquid phase, containing the organic substances and possibly impurities extracted from the bone material, and a second solid hydroxyapatite phase, containing the hydroxyapatite; and —separating the liquid phase and the solid hydroxyapatite phase. The extraction liquid is an aqueous extraction solution brought to a temperature between 150° C. and 300° C. and a pressure between 150 kPa and 350 kPa.

Abstract: An abuse deterrent transdermal patch comprising a multilaminate. The multilaminate can comprise a first layer comprising an opioid analgesic compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable pressure sensitive adhesive. The multilaminate can further comprise a second layer comprising an opioid antagonist, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adhesive. In addition, the multilaminate can further comprise a barrier layer disposed between the first and second layers.

Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.

Abstract: The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.

Abstract: Processes for preparing compositions comprising pharmaceutical agents encapsulated in nanoparticles which provide improved physicochemical and biological properties are described. Also described are compositions comprising water soluble pharmaceutical agents which provide extended release of the pharmaceutical agent. Processes are described for preparing compositions which increase the aqueous availability of compounds with low water solubility.

Abstract: The present application discloses a method for treating acute and chronic sinusitis, and in particular, severe chronic sinusitis by exposing affected tissue of the sinus and contiguous tissue in the, nasal cavity and greater oral cavity to effective amounts of chlorine dioxide as a bioactive agent. Compositions and methods of treatment are disclosed herein.

Abstract: Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165 (165Ho) and dysprosium-164 (164Dy), are disclosed in this application. The iron garnet (e.g., HoIG and DyIG) nanoparticles and iron garnet particles can prepared using hydroxide co-precipitation methods. In some embodiments, radiosensitizers can be loaded on radioactive magnetic nanoparticles or radioactive iron garnet particles and, optionally, coated with suitable lipid bilayers. Methods of using the disclosed nanoparticles and particles for mediating therapeutic benefit in diseases responsive to radiation therapy are also provided. Another aspect of the invention provides films, electrospun fabrics or bandage coverings for the delivery of radiation to the site of a skin lesion amenable to treatment with radiation (e.g., skin cancers or psoriasis).

Abstract: Described herein are pharmaceutical enteric soft capsules that do not contain gelatin as a film-forming polymer. In particular, compositions and methods for manufacturing enteric soft capsules comprising carrageenans as film forming polymers are disclosed.

Abstract: The present invention is directed to combination sunscreen and insect repellant compositions. The combination sunscreen and insect repellant compositions contain (i) diethyl toluamide (or N,N-Diethyl-3-methylbenzamide or DEET), (ii) one or more sunscreen components, with each sunscreen component being capable of absorbing ultraviolet light rays, and (iii) a polymeric binder system. The combination sunscreen and insect repellant compositions may contain additional composition components such as butyloctyl salicylate, a crosslinked polyacrylate polymer, and deionized water. The present invention is also directed to methods of making and using combination sunscreen and insect repellant compositions.

Abstract: A topical antifungal composition for treating onychomycosis includes a terbinafine and/or a pharmaceutically acceptable salt thereof in an amount of from 9% to 11% by weight of the composition, a hydroxypropyl chitosan in an amount of from 0.1% to 0.6% by weight of the composition, water in an amount of from 10.0% to 40.0% by weight of the composition, and a C1-C4 alkanol in an amount of from 60% to 80% by weight of the composition.

Abstract: A pituitous silicone fluid includes a hydrosilylation reaction product and a carrier fluid. The hydrosilylation reaction product is the reaction product of a first linear organopolysiloxane and a second linear organopolysiloxane. The first linear organopolysiloxane includes (R1R2R3SiO1/2) and (R4R5SiO2/2) units. Each of R1-R5 is independently a hydrocarbon group so long as at least one of R1-R5 is an alkenyl group. In addition, the first linear organopolysiloxane has a degree of polymerization of from 100 to 15,000. The second linear organopolysiloxane includes (R6R7R8SiO1/2) and (R9R10SiO2/2) units. Each of R6-R10 is independently a hydrocarbon group, polyether group, siloxane group, or polyol group, so long as at least one of R6-R10 is a hydrogen atom. In addition, the second linear organopolysiloxane has a degree of polymerization of from 4 to 1,000. The hydrosilylation reaction product includes alkenyl or Si—H functionality. Personal care compositions can include the pituitous silicone fluid.

Abstract: The present invention relates to a cosmetic composition which is an antiperspirant and/or deodorant fluid composition to be applied to the human skin, the composition being a non-aluminum based fluid composition free from alcohols and oils, comprising sodium or potassium bicarbonate as the essential deodorizing agent.